Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 23
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1101 | AICHI STEEL | 13 | 00% | 3 | 10 | 2022–2024 |
| 1102 | AIXSCAN | 13 | 00% | 0 | 13 | 2022–2023 |
| 1103 | ALLOGENE THERAPEUTICS | 13 | 00% | 3 | 10 | 2022–2026 |
| 1104 | APOLLO TYRES GLOBAL R D | 13 | 215.4% | 0 | 11 | 2022–2025 |
| 1105 | ARBOR BIOTECHNOLOGIES | 13 | 00% | 7 | 6 | 2022–2025 |
| 1106 | BIOCORP PRODUCTION | 13 | 430.8% | 0 | 9 | 2022–2025 |
| 1107 | BLUEPRINT MEDICINES | 13 | 17.7% | 3 | 9 | 2022–2026 |
| 1108 | C2CNT | 13 | 323.1% | 4 | 6 | 2022–2024 |
| 1109 | CARRIER JAPAN | 13 | 00% | 0 | 13 | 2024–2025 |
| 1110 | CHONGQING LE MARK TECHNOLOGY | 13 | 323.1% | 0 | 10 | 2022–2025 |
| 1111 | COMPOSECURE | 13 | 753.8% | 0 | 6 | 2020–2026 |
| 1112 | CONSTRUCTION RESEARCH TECHNOLOGY | 13 | 00% | 1 | 12 | 2022–2025 |
| 1113 | CRANE | 13 | 215.4% | 1 | 10 | 2021–2025 |
| 1114 | DELLNER BUBENZER | 13 | 00% | 0 | 13 | 2023–2026 |
| 1115 | ENCAPSYS | 13 | 00% | 0 | 13 | 2022–2026 |
| 1116 | EVAPCO | 13 | 00% | 0 | 13 | 2022–2026 |
| 1117 | EVE ENERGY | 13 | 00% | 0 | 13 | 2024–2025 |
| 1118 | FANUC | 13 | 17.7% | 0 | 12 | 2020–2025 |
| 1119 | FORM ENERGY | 13 | 17.7% | 0 | 12 | 2022–2025 |
| 1120 | FULIAN PRECISION ELECTRONICS TIANJIN | 13 | 00% | 0 | 13 | 2024–2025 |
| 1121 | GAMMADELTA THERAPEUTICS | 13 | 00% | 1 | 12 | 2022–2024 |
| 1122 | GIESECKE DEVRIENT EPAYMENTS | 13 | 215.4% | 0 | 11 | 2018–2025 |
| 1123 | GRUNDFOS HOLDING A S | 13 | 323.1% | 0 | 10 | 2022–2026 |
| 1124 | HEPTARES THERAPEUTICS | 13 | 00% | 5 | 8 | 2022–2023 |
| 1125 | HETTICH ONI KG | 13 | 430.8% | 4 | 5 | 2021–2025 |
| 1126 | HIGHLEVEL | 13 | 00% | 0 | 13 | 2024–2025 |
| 1127 | HUAWEI CLOUD COMPUTING TECHNOLOGIES | 13 | 753.8% | 0 | 6 | 2020–2025 |
| 1128 | IBIDEN | 13 | 215.4% | 0 | 11 | 2022–2026 |
| 1129 | INTERNATIONAL FLAVORS FRAGRANCES | 13 | 00% | 0 | 13 | 2022–2026 |
| 1130 | INTEVA PRODUCTS | 13 | 00% | 1 | 12 | 2022–2025 |
| 1131 | IVANTI | 13 | 00% | 0 | 13 | 2023–2026 |
| 1132 | KOCHER PLASTIK MASCHINENBAU | 13 | 17.7% | 0 | 12 | 2017–2025 |
| 1133 | LUNELLA BIOTECH | 13 | 215.4% | 0 | 11 | 2022–2026 |
| 1134 | LYTEN | 13 | 00% | 0 | 13 | 2022–2025 |
| 1135 | METSO METALS | 13 | 00% | 0 | 13 | 2023–2025 |
| 1136 | MINDSET PHARMA | 13 | 00% | 0 | 13 | 2022–2025 |
| 1137 | MITSUBISHI ELECTRIC MOBILITY | 13 | 00% | 0 | 13 | 2025–2025 |
| 1138 | MITSUI KINZOKU | 13 | 00% | 0 | 13 | 2025–2026 |
| 1139 | NEC PLATFORMS | 13 | 861.5% | 3 | 2 | 2022–2024 |
| 1140 | NEWSOUTH INNOVATIONS PTY | 13 | 00% | 2 | 11 | 2022–2025 |
| 1141 | NIPPON TELEGRAPH AND TELEPHONE | 13 | 323.1% | 1 | 9 | 2022–2024 |
| 1142 | NTHALMIC HOLDING PTY | 13 | 215.4% | 0 | 11 | 2022–2025 |
| 1143 | NURIX THERAPEUTICS | 13 | 215.4% | 0 | 11 | 2021–2026 |
| 1144 | OMV DOWNSTREAM | 13 | 00% | 0 | 13 | 2024–2025 |
| 1145 | PEGATRON | 13 | 430.8% | 1 | 8 | 2022–2024 |
| 1146 | PRELUDE THERAPEUTICS | 13 | 00% | 1 | 12 | 2022–2025 |
| 1147 | PROMAXO | 13 | 17.7% | 0 | 12 | 2021–2025 |
| 1148 | REALD SPARK | 13 | 00% | 4 | 9 | 2022–2024 |
| 1149 | REFLEXION MEDICAL | 13 | 17.7% | 2 | 10 | 2020–2025 |
| 1150 | REMIX THERAPEUTICS | 13 | 17.7% | 0 | 12 | 2022–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →